Patents Assigned to Augusta University Research Institute
  • Patent number: 10813905
    Abstract: Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 27, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Vadivel Ganapathy, Pamela M. Martin
  • Patent number: 10793816
    Abstract: A dual chamber bioreactor for producing complex, multilayer tissue, organs, organ parts, and skin replacements has been developed. The bioreactor is modular and incorporates a removable tissue culture cassette. By rotating the dual chamber bioreactor along the horizontal axis, different populations of cells with different growth requirements can be cultured on the different surfaces of the tissue culture cassette that are exposed to different media reservoirs. Culturing different populations of cells on different surfaces of the tissue culture cassette enables the production of multilayer tissue and organs. The tissue culture cassette can contain one or more discrete tissue culture sections.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: October 6, 2020
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventors: Paul M. Weinberger, Frederick A. Rueggeberg, Donald J. Mettenburg, Tanner Mobley
  • Publication number: 20200289444
    Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.
    Type: Application
    Filed: March 14, 2020
    Publication date: September 17, 2020
    Applicants: The Regents of the University of California, Augusta University Research Institute
    Inventors: Weimbs Thomas, Jacob Torres, Muthusamy Thangaraju
  • Patent number: 10722528
    Abstract: Calprotectin inhibitors and derivatives thereof, and methods of using them for inhibiting or reducing metastatis and treating cancer are provided. The pharmaceutical formulations prepared from the compounds can be used in the treatment of cancer either as a single agent or in combination with at least one other cancer therapeutic, chemotherapeutic or anti-cancer agent.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: July 28, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Hasan Korkaya, Eunmi Lee
  • Patent number: 10689654
    Abstract: A bivalent siRNA chimera platform capable of efficiently delivering and silencing two or more genes in vivo or in vitro is provided. Methods of using the bivalent siRNA chimeras for selectively targeting cells to down-regulate the expression of multiple genes are also provided.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 23, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventor: Hong Yan Liu
  • Patent number: 10660967
    Abstract: Curcumin-based conjugates and methods of use thereof are provided. Pharmaceutical compositions including an effective amount of one or more curcumin conjugates are also provided. In particular embodiments, the compositions are formulated for oral delivery. The conjugates and pharmaceutical compositions thereof can be administered to a subject in need thereof to treat a host of diseases and disorders including but not limited to, cancer, inflammation, and microbial growth.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: May 26, 2020
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventor: Siva Panda
  • Patent number: 10588966
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 17, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Patent number: 10577371
    Abstract: Compositions for the inhibition of SUV39H1 methyltransferase activity and methods of use thereof are provided. The disclosed compositions may be used for treating certain types of cancer, inducing apoptosis in a cancer cell, increasing cell sensitivity to FasL-induced apoptosis, and overcoming cancer cell resistance to apoptosis and/or certain types of cancer immunotherapy.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 3, 2020
    Assignees: Augusta University Research Institute, Inc., Department of Veterans Affairs
    Inventors: Chunwan Lu, Iryna Lebedyeva, Kebin Liu
  • Patent number: 10525049
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: January 7, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva
  • Patent number: 10478491
    Abstract: As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an OX40 agonist and an Indoleamine 2,3-dioxygenase (IDO) inhibitor with the tumor antigen.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 19, 2019
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventor: Samir Khleif
  • Patent number: 10368848
    Abstract: In some embodiments, a cell collection device includes a sample brush including a proximal end, a distal end, and outwardly extending bristles provided at the distal end, and an outer sleeve adapted to receive the sample brush, the sleeve including a proximal end and a distal end, wherein the sleeve can be linearly slid along the length of the brush to encapsulate the bristles after they have been used to collect cells from a patient.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: August 6, 2019
    Assignee: Augusta University Research Institute, Inc.
    Inventor: Daron G. Ferris
  • Patent number: 10342868
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: July 9, 2019
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Patent number: 10292978
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 21, 2019
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva
  • Patent number: 10201588
    Abstract: Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (GHRH) antagonist or variant thereof to the subject.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: February 12, 2019
    Assignees: UNIVERSITY OF MIAMI, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventors: Maritza Romero-Lucas, Andrew Schally, Rudolf Lucas, Neal Weintraub
  • Patent number: 10201633
    Abstract: Compositions and methods for glass composites suitable for tissue augmentation, biomedical, and cosmetic applications are provided. The glass microsphere component of the composites are biologically inert, non-reactive and act as a nearly permanent tissue filler. One embodiment provides a tissue augmentation composite containing an effective amount of solid glass microspheres, hollow glass microspheres, porous wall hollow glass microspheres, or combinations thereof with a suitable biocompatible matrix to serve as a bulking agent when injected into a patient. The compositions can be used for soft or hard tissue augmentation as well as delivery of cargos on demand.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: February 12, 2019
    Assignees: Augusta University Research Institute, Inc., Applied Research Center, Inc.
    Inventors: Paul M. Weinberger, William D. Hill, George G. Wicks
  • Patent number: 10159731
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 25, 2018
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Patent number: 10143377
    Abstract: Methods for remotely measuring or monitoring one or more physiological parameters in a subject, such as blood volume pulse, heart rate, respiratory wave, or respiration rate, are provided. The methods include capturing a series of images of the subject, and processing the images to obtain physiological parameters of interest. These methods can be used to analyze single channel signals, including signals obtained from active night vision cameras. As a result, these methods can be used to measure or monitor one or more physiological parameters in both daylight and low-light conditions. Also provided are methods of removing false positives. Systems for remotely measuring or monitoring one or more physiological parameters in a subject, as well as methods of using thereof, are also provided.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: December 4, 2018
    Assignees: Augusta University Research Institute, Inc., Banna Biomedical Reseach Institute
    Inventors: Joseph Z. Tsien, Meng Li, Fang Zhao, Yi Qian
  • Publication number: 20180322800
    Abstract: A system for providing interaction between a virtual human and a user, the system comprising: a tangible interface providing a physical interface between the user and the virtual human, an imaging system directed towards the physical interface to provide images of the user interacting with the tangible interface; a tracking system tracking at least one position or the user; a microphone capturing speech from the user; a simulation system receiving inputs from the tangible interface, the imaging system, the tracking system and the microphone, the simulation system generating output signals corresponding to the virtual human; and a display presenting the output signals to the user.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 8, 2018
    Applicants: University of Florida Research Foundation, Incorporated, Augusta University Research Institute, Inc.
    Inventors: Benjamin Chak Lum Lok, David Scott Lind, Juan Carlos Cendan, Andrew Brian Raij, Brent H. Rossen, Aaron Andrew Kotranza, Kyle John Johnsen
  • Patent number: 10117900
    Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: November 6, 2018
    Assignees: ATHERSYS, INC., Augusta University Research Institute, Inc.
    Inventors: Robert Mays, Robert J. Deans, David C. Hess, James E. Carroll, Cesar V. Borlongan
  • Publication number: 20180296609
    Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.
    Type: Application
    Filed: December 20, 2017
    Publication date: October 18, 2018
    Applicant: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventors: Robert MAYS, Robert J. Deans, David C. Hess, James E. Carroll, Cesar V. Borlongan